View Older Stories View More Recent Stories

Sep 22, 2021 09:00AM Amgen Releases 8th Edition of Biosimilar Trends Report
Sep 21, 2021 05:53AM Amgen (AMGN) Wins Otezla Patent Case
Sep 20, 2021 07:02PM Amgen Wins Patent Case on Otezla® (apremilast)
Sep 16, 2021 06:23AM Amgen (AMGN) New LUMAKRAS™ With Vectibix® Data Shows Encouraging Efficacy And Safety In Patients With KRAS G12C-Mutated Colorectal Cancer
Sep 16, 2021 04:30AM LUMAKRAS™ (Sotorasib) Combined With Vectibix® (Panitumumab) Showed Encouraging Efficacy And Safety In Patients With KRAS G12C-Mutated Colorectal Cancer
Sep 14, 2021 04:00PM Amgen And The Lundquist Institute Announce That Diadem Therapeuctics Will Receive The First Amgen Golden Ticket To BioLabs LA
Sep 13, 2021 04:15PM Amgen To Present At The 2021 Bank of America Merrill Lynch Global Healthcare Conference
Sep 13, 2021 04:00PM Amgen To Webcast Investor Call At ESMO 2021
Sep 13, 2021 09:00AM Amgen To Showcase New Data From Inflammation Portfolio At EADV Virtual Congress 2021
Sep 9, 2021 05:00PM Amgen to Present at the 19th Annual Morgan Stanley Global Healthcare Conference
Sep 8, 2021 04:00PM Amgen Presents New Data From Thoracic Oncology Portfolio At WCLC21
Sep 5, 2021 07:15AM New Tezepelumab Data Show 86% Reduction In Exacerbations In Patients With Severe Asthma And Comorbid Nasal Polyps
Sep 3, 2021 04:00PM Amgen to Present at the 16th Annual Citi BioPharma Conference
Aug 27, 2021 05:42AM Amgen (AMGN) Announces Positive HUYGENS Phase 3 Data Showing Repatha Improves Features Of Plaque Stability In Patients With Acute Coronary Syndrome (ACS)
Aug 27, 2021 04:30AM New Data At ESC Congress 2021 Shows Repatha® (evolocumab) Improves Features Of Plaque Stability In Patients With Acute Coronary Syndrome (ACS)
Aug 3, 2021 04:01PM Amgen Reports Second Quarter 2021 Financial Results
Jul 30, 2021 04:00PM Amgen Announces 2021 Third Quarter Dividend
Jul 30, 2021 05:19AM Amgen (AMGN) Appoints S. Omar Ishrak to its Board
Jul 29, 2021 07:10PM Amgen Appoints S. Omar Ishrak To Board Of Directors
Jul 29, 2021 04:00PM Amgen Announces Webcast Of 2021 Second Quarter Financial Results
Jul 27, 2021 04:20PM Amgen (AMGN) Acquires Teneobio For $900M With Future Contingent Milestone Payments
Jul 27, 2021 04:19PM Amgen To Acquire Privately Held Teneobio For $900 Million In Cash With Future Contingent Milestone Payments
Jul 14, 2021 08:00AM Amgen And The International Federation of Psoriasis Associations Launch UPLIFT Innovation Challenge
Jul 8, 2021 02:00AM Tezepelumab Granted Priority Review By U.S. FDA
Jul 1, 2021 05:04PM Lab Corp. (LH) Launches Companion Diagnostic for Amgen’s Newly-approved Lung Cancer Therapy
Jul 1, 2021 05:03PM Labcorp Launches Companion Diagnostic for Amgen’s Newly-approved Lung Cancer Therapy
Jun 23, 2021 06:15AM Amgen (AMGN) Announces Approval Of Aimovig In Japan For The Suppression Of Onset Of Migraine Attacks In Adults
Jun 23, 2021 04:00AM Amgen Announces Approval Of Aimovig® (Erenumab) In Japan For The Suppression Of Onset Of Migraine Attacks In Adults
Jun 15, 2021 08:00AM Acclaimed Makeup Artist Allan Avendaño Opens Up About Personal Skin Condition: Provides INSIDE LOOK At Life With Plaque Psoriasis
Jun 4, 2021 05:00PM Amgen To Present At The Goldman Sachs 42nd Annual Global Healthcare Conference
Jun 4, 2021 04:01PM Amgen (AMGN) Announces Results From Phase 2 CodeBreaK 100 Show LUMAKRAS Is The First And Only KRAS G12C Inhibitor With Overall Survival Data
Jun 4, 2021 04:00PM Results From Phase 2 CodeBreaK 100 Show LUMAKRAS™ (sotorasib) Is The First And Only KRAS G12C Inhibitor With Overall Survival Data
Jun 4, 2021 09:00AM Phase 2 Fight Trial Continues To Show Improved Overall Survival With Bemarituzumab Plus Chemotherapy In Patients With FGFR2b+ Gastric And Gastroesophageal Cancers
Jun 1, 2021 07:00PM Amgen to Webcast Investor Meeting at ASCO 2021
Jun 1, 2021 04:00AM Amgen and Kyowa Kirin to Jointly Develop and Commercialize KHK4083, a Phase 3-Ready, Potential First-In-Class Treatment for Atopic Dermatitis
May 28, 2021 05:00PM Amgen To Present At The 2021 Jefferies Healthcare Conference
May 28, 2021 12:48PM Amgen (AMGN) Confirms FDA Approves LUMAKRAS (Sotorasib)
May 28, 2021 12:47PM FDA Approves LUMAKRAS™ (Sotorasib), The First And Only Targeted Treatment For Patients With KRAS G12C-Mutated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
May 19, 2021 07:15PM Amgen To Present AT the Cowen 2nd Annual Virtual Oncology Innovation Summit
May 19, 2021 05:00PM Amgen To Showcase New Data From Oncology Portfolio At ASCO 2021
May 13, 2021 07:15AM AstraZeneca (AZN), Amgen (AMGN) New Tezepelumab Data Continue to Strengthen Profile for a Broad Population of Severe Asthma Patients
May 13, 2021 06:24AM Amgen (AMGN) Announces New Tezepelumab Data Continue To Strengthen Profile For A Broad Population Of Severe Asthma Patients
May 13, 2021 02:00AM New Tezepelumab Data Continue To Strengthen Profile For A Broad Population Of Severe Asthma Patients
May 11, 2021 09:04AM Amgen (AMGN) Announces Efficacy Of Repatha Across High-Risk Patient Populations Reinforced At ACC.21
May 11, 2021 09:00AM Efficacy Of Repatha® (Evolocumab) Across High-Risk Patient Populations Reinforced At ACC.21
May 10, 2021 09:02AM Amgen (AMGN) Announces Tezepelumab Biologics License Application Submitted To U.S. FDA
May 10, 2021 09:00AM Amgen Announces Tezepelumab Biologics License Application Submitted To U.S. FDA
May 6, 2021 04:00PM Amgen To Present At The 2021 Bank of America Merrill Lynch Healthcare Conference
May 5, 2021 09:02AM Amgen (AMGN) Announces FDA Accepts its sNDA For Otezla For Adults With Mild-To-Moderate Plaque Psoriasis
May 5, 2021 09:00AM FDA Accepts Amgen's Supplemental New Drug Application For Otezla® (apremilast) For Adults With Mild-To-Moderate Plaque Psoriasis
View More Recent Stories View Older Stories